Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients

Q3 Neuroscience

eNeurologicalSci Pub Date : 2024-06-12 DOI:10.1016/j.ensci.2024.100511

Parisa Sharifi , Nasim Rezaeimanesh , Amir Moradi , Abdorreza Naser Moghadasi

{"title":"Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients","authors":"Parisa Sharifi , Nasim Rezaeimanesh , Amir Moradi , Abdorreza Naser Moghadasi","doi":"10.1016/j.ensci.2024.100511","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients with multiple sclerosis (MS) are at higher risk of having infections due to receiving disease modifying therapies. The current study was conducted among Iranian MS patients who had experienced at least one episode of COVID-19 infection in order to evaluate the effects of COVID-19 vaccination on symptoms of their infection. Data on demographic information, MS characteristics, COVID-19 infection details, and vaccination status were collected. Statistical analyses, were performed to evaluate the association between vaccination and symptoms of COVID-19 infection.</p></div><div><h3>Methods</h3><p>This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients' who declared to be vaccinated was checked by their COVID-19 vaccination card.</p></div><div><h3>Results</h3><p>A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (<em>P</em>-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, <em>P</em>-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, <em>P</em>-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39).</p></div><div><h3>Conclusion</h3><p>COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination.</p></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"36 ","pages":"Article 100511"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405650224000182/pdfft?md5=10e489228c32598c74a318434d7b8e4c&pid=1-s2.0-S2405650224000182-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"eNeurologicalSci","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405650224000182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Neuroscience","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Patients with multiple sclerosis (MS) are at higher risk of having infections due to receiving disease modifying therapies. The current study was conducted among Iranian MS patients who had experienced at least one episode of COVID-19 infection in order to evaluate the effects of COVID-19 vaccination on symptoms of their infection. Data on demographic information, MS characteristics, COVID-19 infection details, and vaccination status were collected. Statistical analyses, were performed to evaluate the association between vaccination and symptoms of COVID-19 infection.

Methods

This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients' who declared to be vaccinated was checked by their COVID-19 vaccination card.

Results

A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (P-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, P-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, P-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39).

Conclusion

COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination.

查看原文本刊更多论文

接种疫苗对多发性硬化症患者 COVID-19 感染症状的影响

背景多发性硬化症（MS）患者因接受疾病调整疗法而感染的风险较高。本研究的对象是至少经历过一次 COVID-19 感染的伊朗多发性硬化症患者，目的是评估接种 COVID-19 疫苗对感染症状的影响。研究收集了有关人口统计学信息、多发性硬化症特征、COVID-19 感染详情和疫苗接种情况的数据。这项横断面研究的对象是确诊的多发性硬化症患者。通过在线问卷收集了人口统计学数据和 COVID-19 相关症状。结果共有 236 名多发性硬化症患者参与了研究。大多数患者为女性（79.7%），平均年龄为（36.1 ± 7.9）岁。其中，72.5%的参与者在首次感染 COVID-19 前接种过 COVID-19 疫苗。分析表明，接种疫苗者与未接种疫苗者在呼吸道症状（P 值：0.01）和头痛（P 值：0.04）的发生率上存在明显差异。逻辑回归分析显示，接种疫苗的多发性硬化症患者在下一次感染 COVID-19 时出现呼吸道症状（OR：0.29，95% CI：0.16 至 0.53，P 值：0.001）或头痛（OR：0.50，95% CI：0.25 至 0.98，P 值：0.04）的几率较低。此外，正在接受免疫抑制剂治疗的多发性硬化症患者出现呼吸道症状的可能性较低（OR：0.35，95% CI：0.16 至 0.77，P 值：0.009），但出现头痛的可能性较低（OR：0.69，95% CI：0.30 至 1.60，P 值：0.39）。此外，正在接受免疫抑制剂治疗的患者也可从接种 COVID-19 疫苗中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

eNeurologicalSci Neuroscience-Neurology

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

62 days

期刊介绍： eNeurologicalSci provides a medium for the prompt publication of original articles in neurology and neuroscience from around the world. eNS places special emphasis on articles that: 1) provide guidance to clinicians around the world (Best Practices, Global Neurology); 2) report cutting-edge science related to neurology (Basic and Translational Sciences); 3) educate readers about relevant and practical clinical outcomes in neurology (Outcomes Research); and 4) summarize or editorialize the current state of the literature (Reviews, Commentaries, and Editorials). eNS accepts most types of manuscripts for consideration including original research papers, short communications, reviews, book reviews, letters to the Editor, opinions and editorials. Topics considered will be from neurology-related fields that are of interest to practicing physicians around the world. Examples include neuromuscular diseases, demyelination, atrophies, dementia, neoplasms, infections, epilepsies, disturbances of consciousness, stroke and cerebral circulation, growth and development, plasticity and intermediary metabolism. The fields covered may include neuroanatomy, neurochemistry, neuroendocrinology, neuroepidemiology, neurogenetics, neuroimmunology, neuroophthalmology, neuropathology, neuropharmacology, neurophysiology, neuropsychology, neuroradiology, neurosurgery, neurooncology, neurotoxicology, restorative neurology, and tropical neurology.